NEW YORK, NY / ACCESSWIRE / July 19, 2016 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of ZIOPHARM Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ: ZIOP). Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.
The investigation concerns whether Ziopharm and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On July 14, 2016, Ziopharm revealed that a brain cancer patient in an ongoing clinical trial had died after being treated with Ad-RTS-hIL-12, the Company's experimental gene therapy. A Ziopharm spokesman commented that Ziopharm had not yet informed the U.S. Food and Drug Administration of the death. Ziopharm then disclosed a second death of a patient in clinical study, but said the death was unrelated to Ad-RTS-hIL-12. The Street reported and quoted an email from Jefferies & Co. investment bank to prospective investors, that as a result of the patient death and the way in which Ziopharm had disclosed it, a deal to raise as much as $50 million in a stock offering was abandoned. Following this news, Ziopharm dropped as much as $1.11 per share, or 19.58%, to just $4.56 per share during intraday trading on July 15, 2016.
If you purchased Ziopharm shares or if you are aware of any facts relating to this investigation, you can assist this investigation by visiting the firm's site: http://www.bgandg.com/#!ziop/xauda. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
ReleaseID: 442553
